What Is the Export Manufacturing Registration System — Key Changes Under the CDMO Special Act
The Global Bio-Pharmaceutical CDMO Special Act, set to take effect in the second half of 2026, represents a watershed moment for Korea's biomanufacturing sector. Under the existing Pharmaceutical Affairs Act, export-only manufacturing facilities had to follow the same licensing procedures as domestic-market operations. The new Export Manufacturing Registration System creates a dedicated regulatory pathway for companies manufacturing biopharmaceuticals exclusively for export.
Here are the key differences:
This reform targets not only major CDMOs like Samsung Biologics and Celltrion but also small and mid-sized biotech companies with annual revenues under KRW 50 billion, aiming to lower their barriers to global market entry. The government has set a goal of expanding domestic CDMO revenue to KRW 30 trillion by 2027, making now the ideal time to begin preparations.
MFDS GMP Compliance Certification and API Certification Framework
The central gateway to export manufacturing registration is MFDS GMP compliance certification. In preparation for the Special Act, the Ministry of Food and Drug Safety (MFDS) is developing GMP certification standards tailored specifically to CDMO manufacturing sites.
Key GMP Compliance Certification Requirements
Active Pharmaceutical Ingredient (API) Certification
The API certification system is also being formalized. APIs that receive prior MFDS certification will benefit from streamlined import clearance documentation, reducing average customs processing from 15–20 days to under 5 days.
Leveraging Regulatory Support Services
MFDS is offering pre-consultation and technical advisory services ahead of the Special Act's implementation:
Practical Preparation Checklist for SME Biotech Companies
1. Facility and Equipment Investment Priorities
SMEs preparing for GMP certification with limited budgets must clearly prioritize their investments:
2. Workforce Development and Quality Culture
3. Government Support Programs
KITIM Consulting Implications
The implementation of the export manufacturing registration system presents both opportunities and challenges for Korean biotech companies. From GMP compliance certification preparation to government subsidy applications, a systematic strategy is the key to success.
KITIM (Korea Institute of Technology Innovation Management) provides GMP certification consulting and government funding program integration strategies for the bio-pharmaceutical sector. We offer end-to-end support covering export manufacturing registration roadmap development, R&D project planning, and facility investment grant applications. Contact KITIM today for a customized consulting engagement.